Short Interest in Immatics (NASDAQ:IMTXW) Expands By 2,257.1%

Immatics (NASDAQ:IMTXW) was the recipient of a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 16,500 shares, an increase of 2,257.1% from the November 30th total of 700 shares. Based on an average daily volume of 33,600 shares, the short-interest ratio is currently 0.5 days.

Immatics Trading Up 10.6 %

IMTXW stock opened at $0.20 on Friday. Immatics has a 1 year low of $0.16 and a 1 year high of $4.14. The stock has a 50-day simple moving average of $0.59 and a 200-day simple moving average of $1.95.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.